A signing ceremony and press conference was held announcing Hikma’s exclusive rights for registering and marketing the new treatment.
Mr. Mazen Darwazeh, Hikma Pharmaceuticals Executive Vice Chairman and CEO of the Middle East and North Africa (MENA) region, and Professor. Juergen Engel, Ph.D, President and CEO of Aeterna Zentaris, signed the exclusivity agreement in the presence of executives from both companies and members of the media.
Perifosine, an oral Akt inhibitor, is currently undergoing two Phase 3 clinical trials for the treatment of colorectal cancer and multiple myeloma in the United States and Europe. It will be one of the most advanced oncology products Hikma provides for countering these diseases, building on Hikma’s mission to ensure that the healthcare sector in the MENA region is as well-equipped as possible in combatting cancer.
The agreement grants Hikma as well a license to enroll patients in clinical trials for Perifosine, in addition to the possibility of manufacturing the product in its specialized manufacturing facilities.
Accordingly Hikma Pharmaceuticals will be the first and only company in the region that is investing in cancer medications during its early stage of developments. Hikma currently owns exclusive licensing rights to register and market Perifosine in MENA for the next ten years thus helping to bring hope to patients with these types of cancer.
Hikma will leverage its unique presence, marketing expertise, and its legislative knowledge of the MENA region to market Perifosine to tackle this challenging disease.
Hikma has two oncology manufacturing facilities located in Germany and Jordan, and has a portfolio of cancer medicines registered in many countries such as the United States, Germany, Portugal, and in the Middle East.
Mr. Mazen Darwazah expressed his pride in signing the agreement with Aeterna Zentaris, which is a leading research company in the oncology field, with many promising oncology products in the pipeline.
He said: “The agreement provides an opportunity to supply patients in the region with one of the most important products for the treatment of colorectal cancer, and multiple myeloma.”
Regarding Hikma Pharmaceuticals’ future vision, Mr. Darwazah went on to say, “Hikma Pharmaceuticals’ goal is to equip the medical sector regionally with high quality pioneering medicinal options to reduce their dependency on a single source for treatment.
Prof. Juergen Engel stated, “Hikma Pharmaceuticals has a proven track record in oncology and is the leading pharmaceutical company in the region, which is why we believe Hikma is the perfect fit for the development and commercialization of Perifosine in the region.”
Thursday, November 24- 2011 @ 11:52 UAE local time (GMT+4) Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of Mediaquest FZ LLC.